Abstract | BACKGROUND: METHODS: Eighty-three patients with serum [Na] less than 130 mEq/L were stratified by volume status and randomly assigned to placebo or conivaptan 40 or 80 mg/d for 5 days. RESULTS:
Conivaptan increased the baseline-adjusted area under the serum [Na]-time curve significantly more than placebo (P = 0.0001). Patients given either dose of conivaptan demonstrated a serum [Na] of 4 mEq/L or greater above baseline significantly faster than those given placebo (P < 0.001) and maintained that increase for a greater total time (P = 0.0001). The least squares mean change in serum [Na] from baseline to end of treatment was also significantly greater with conivaptan 40 and 80 mg/d (6.8 and 8.8 mEq/L, respectively) (P = 0.0001) than that with placebo (1.2 mEq/L). The percentage of patients who obtained an increase from baseline in serum [Na] of 6 mEq/L or greater or normal serum [Na] was significantly higher among patients given conivaptan 40 and 80 mg/d (67% and 88%, respectively) than among those given placebo (20%; P < 0.001). Conivaptan was well tolerated; the most frequent adverse events were urinary tract infection, anemia, pyrexia, cardiac failure, hypotension, and hypokalemia. CONCLUSION: Oral conivaptan was effective in increasing serum [Na] in patients with euvolemic or hypervolemic hyponatremia and had a favorable safety profile.
|
Authors | Djillali Annane, Guy Decaux, Neila Smith, Conivaptan Study Group |
Journal | The American journal of the medical sciences
(Am J Med Sci)
Vol. 337
Issue 1
Pg. 28-36
(Jan 2009)
ISSN: 0002-9629 [Print] United States |
PMID | 19057376
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antidiuretic Hormone Receptor Antagonists
- Benzazepines
- conivaptan
- Sodium
|
Topics |
- Administration, Oral
- Adult
- Aged
- Antidiuretic Hormone Receptor Antagonists
- Benzazepines
(administration & dosage, adverse effects, therapeutic use)
- Double-Blind Method
- Female
- Humans
- Hyponatremia
(blood, drug therapy)
- Male
- Middle Aged
- Sodium
(blood)
|